Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
about
Potential use of rapamycin in HIV infectionTargeting the mTOR kinase domain: the second generation of mTOR inhibitorsClinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewSelective inhibition of retinal angiogenesis by targeting PI3 kinaseThe susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposingOverexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-ATargeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Recent advances in the discovery of small molecule mTOR inhibitors.Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancerSerratia marcescens is able to survive and proliferate in autophagic-like vacuoles inside non-phagocytic cellsThe phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.Cell metabolism: an essential link between cell growth and apoptosisSlug enhances invasion ability of pancreatic cancer cells through upregulation of matrix metalloproteinase-9 and actin cytoskeleton remodeling.Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition.Drugging the PI3 kinome: from chemical tools to drugs in the clinic.Role of PI4K and PI3K-AKT in ERK1/2 activation by GnRH in the pituitary gonadotropes.Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches.Novel inhibitors of the PI3K family.A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents.Apoptosis and autophagy: Targeting autophagy signalling in cancer cells -'trick or treats'?Modulating the tumor microenvironment to increase radiation responsiveness.Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells.Inhibitors of phosphatidylinositol-3-kinase in cancer therapyOncolytic-adenovirus-expressed RNA interference for cancer therapy.Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.Beyond chemotherapy: new agents for targeted treatment of lymphomaGlucose metabolism disorders and the risk of cancer.Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.Targeted drug therapy: the platelet side.Advances in malignant glioma drug discovery.Mechanisms of acquired resistance to targeted cancer therapies.Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase.Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.
P2860
Q24606795-13CC7C19-E802-4E56-9FE3-5553A09944CFQ24622194-92B3C912-5806-45A2-8866-2E4102D12929Q26770716-6DC3E776-4C7E-43F1-B2FF-9C30DC5ACEA3Q28471888-FB111D08-D74C-48F8-82C4-4709ACAFB913Q28476644-5C4733CB-16FF-45B0-8842-3A5D628549A6Q28828213-5D47A36A-4EA1-409B-AD09-9249E7941A9FQ33493174-FCA101A2-D5FE-417C-976B-155E3C4BF6ABQ33852446-F24BC843-AE99-48EF-BED7-DBFF0B1C28BDQ33882138-E316FFBA-8770-4149-A6BC-755D3B1FAA44Q33967933-6292B463-4A6F-4B17-A821-2F70381B2666Q34013810-63C76EA3-136E-466F-BB86-671A3A297B8BQ34024558-B87B54E6-089F-490E-A6C9-2C555579D6FDQ34193749-2396B165-3D92-4BB6-877B-C98B0242C8AFQ34196216-7911C721-55BA-485C-AE3A-5C7C212038FEQ34440592-C4FF1722-F870-4CF4-870A-342D77073DA7Q35073648-FC284557-8D47-49FA-85AA-500E398A8E33Q35587475-E28916A1-D52B-4F50-8143-634F3D686EAEQ35622141-E262C924-D38B-4EE0-8FA9-BFD1225D14F0Q36090502-72AD2757-E34B-4A5D-BD3C-26E6651F822CQ37227994-9516E411-6E92-4B57-B66B-B6FA5C1D2A70Q37281257-59968DD7-774B-4AF4-A575-5C8D2820DD69Q37281824-80871A05-69DD-43CA-8E9A-6A26E236808BQ37406706-EC97FD46-AB2A-4EC3-AE12-CB2E276348CDQ37489947-B5C91C05-7D1E-44F8-842F-31920BFF8F0EQ37546115-CAD6FC7D-8405-488B-BA11-A6B4436F1DA0Q37552881-8110A62A-A00D-4259-BB5D-FC1C9741A938Q37605154-175BFC79-B74B-4B8F-A71C-E7DEB12A56B3Q37613364-7B128C49-64B3-4467-BA06-C4F600645FFBQ37691008-8F89A769-916F-4FA7-AFCE-01A6FD9BBB52Q37696628-E142D4C5-58C6-4D8D-B1EA-92EA2967B68AQ37777745-49496DED-3695-4E29-8EA1-9DF385EC27ECQ37786716-95689AD4-2B69-4709-AE7F-C5D4DF5C2B95Q37820097-F7A89934-DCB6-4E86-89EC-686DF4804742Q37859317-444A6529-CEB6-4239-AF63-C864B3ADC075Q37886009-157E7AA6-A034-4751-BA47-3F74A94DE342Q37942612-E0465914-4DEF-4A20-84EE-21FA4D99411AQ38014949-DA030899-2EFF-48E9-AF99-DC8B887D87B9Q38034816-3508E1F8-CCFF-4BD4-8E2D-F06B7DA6713AQ38081658-79F879FE-7398-43C1-8D16-F8DD759E12BEQ38227567-1C842BBE-9D08-4B92-A7BA-F3D36BE50346
P2860
Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Take your PIK: phosphatidylino ...... nic and toward cancer therapy.
@en
Take your PIK: phosphatidylino ...... nic and toward cancer therapy.
@nl
type
label
Take your PIK: phosphatidylino ...... nic and toward cancer therapy.
@en
Take your PIK: phosphatidylino ...... nic and toward cancer therapy.
@nl
prefLabel
Take your PIK: phosphatidylino ...... nic and toward cancer therapy.
@en
Take your PIK: phosphatidylino ...... nic and toward cancer therapy.
@nl
P2860
P1476
Take your PIK: phosphatidylino ...... nic and toward cancer therapy.
@en
P2093
Nathan T Ihle
P2860
P356
10.1158/1535-7163.MCT-08-0801
P50
P577
2009-01-01T00:00:00Z